Methods of treatment using human antibodies that bind IL-12
US8865174B2 · kind B2 · utility
Assignee
Inventors
- Jochen G. Salfeld
- Michael Roguska
- Michael Paskind
- Subhashis Banerjee
- Daniel Edward Tracey
- Michael White
- Zehra Kaymakcalan
- Boris Labkovsky
- Paul Sakorafas
- Geertruida M. Veldman
- Amy Venturini
- Angela Widom
- Stuart Friedrich
- Nicholas W. Warne
- Angela Kantor
- John Gawain Elvin
- Alexander Robert Duncan
- Elaine Joy Derbyshire
- Sara Carmen
- Stephen J. Smith
- Thor Las Holtet
- Sarah Leila Du Fou
Key dates
| Filing date | Mar 12, 2012 |
| Grant date | Oct 21, 2014 |
| Priority date | — |
| Expiry date | Mar 12, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.